Can You Have Bariatric Surgery While Taking a GLP-1?

Yes. Taking semaglutide, tirzepatide or liraglutide does not close the door on a bariatric assessment, and current guidance from anaesthesia and surgical societies treats an active GLP-1 prescription as something to plan around rather than a reason to turn someone away. What changes is the practical detail: which medication, what dose, how recently that dose went up, and how your stomach is behaving in the days before an operation. At The Sleeve Clinic one piece of that is fixed rather than individualised — the GLP-1 stops at least two weeks before the operation. The rest gets worked out with the team looking after you. It is not decided by a general rule found online.

People usually arrive at this question sideways. A GLP-1 did something meaningful, and then something shifted — cost, supply, side effects, a plateau, or a growing worry about what happens if the prescription ever stops. Wondering about surgery while still on the medication is not disloyalty to a treatment that worked, and it is better thought through early than in a panic later.

Time on a GLP-1 is part of your treatment history, not a mark against it

The Canadian Adult Obesity Clinical Practice Guidelines state that potential surgical candidates should have a history of identifiable attempts at the medical management of obesity. A course of GLP-1 therapy is exactly that. It is prescribed, dosed, monitored and recorded — evidence of active treatment sitting in your file.

The question usually gets phrased in the room as does being on medication count against me? It does not. Neither the Canadian guidelines nor the 2022 indications published jointly by the American Society for Metabolic and Bariatric Surgery and the International Federation for the Surgery of Obesity and Metabolic Disorders treat current or prior pharmacotherapy as a disqualifier.

The other thing worth saying out loud: regaining weight after stopping a GLP-1 is a physiological response, not a character verdict. The body defends a weight it has adapted to, and appetite signalling returns when the drug suppressing it is withdrawn. What happens to your weight after stopping a GLP-1 covers that mechanism in more depth.

What an assessment actually looks at

A bariatric assessment is broader than a number. The Canadian guidelines describe a multidisciplinary evaluation of medical, mental, nutritional and functional health, with further testing — cardiac, respiratory, metabolic, gastrointestinal, sleep — ordered based on what the history turns up.

Body mass index still forms part of the picture, and the published thresholds are not identical across documents. The Canadian guidelines describe surgery as indicated at a BMI of 35 or above with at least one major obesity-related complication, and at 40 or above independent of complications, with selective consideration between 30 and 34.9 where metabolic disease has not responded to non-surgical treatment. The 2022 ASMBS and IFSO indications set the threshold at a BMI of 35 or above (≥35 kg/m²) regardless of comorbidity, and recommend considering surgery between 30 and 34.9 in the presence of metabolic disease. Individual programs apply these differently.

One question comes up constantly among people currently on a GLP-1: if the medication brought my BMI down, do I still qualify? No single published rule settles this, and programs vary in what they weigh. The Sleeve Clinic looks at all three together: current BMI, highest documented BMI, and the trajectory across both. A number that has come down on medication is read against where it started and how it moved, rather than on its own. The eligibility overview and weight loss calculator are reasonable starting points, and BMI requirements for gastric sleeve surgery works through the thresholds in more detail.

Where a GLP-1 genuinely matters: the day of surgery

GLP-1 receptor agonists slow gastric emptying. That is part of how they work — food stays in the stomach longer, which contributes to the fullness people describe. Under general anaesthesia, a stomach that still holds contents raises the risk of aspiration, where material passes into the airway. That is the concern anaesthetists are managing, and it is a genuine one.

The guidance on how to manage it has moved. In June 2023 the American Society of Anesthesiologists advised holding these medications before elective procedures — daily formulations on the day of surgery, weekly formulations for a week beforehand. In October 2024, five societies including the ASA, ASMBS, the American Gastroenterological Association, the Society of American Gastrointestinal and Endoscopic Surgeons and the International Society for the Perioperative Care of Patients with Obesity published joint guidance replacing that blanket approach with a risk-stratified one. Most patients without elevated risk of delayed gastric emptying can continue their GLP-1 before an elective procedure.

What raises the concern

The factors that guidance flags are specific:

Being in the dose-escalation phase rather than on a stable maintenance dose
Higher doses
Weekly rather than daily formulations
Active gastrointestinal symptoms — nausea, vomiting, abdominal pain, dyspepsia, constipation
Conditions already associated with delayed emptying, such as gastroparesis, bowel dysmotility or Parkinson's disease

Where concern exists, the common mitigation is a clear liquid diet for at least 24 hours before the procedure, alongside standard fasting and sometimes a modified anaesthetic technique. Guidance also differs by region: consensus statements published in 2025 by the Society for Perioperative Assessment and Quality Improvement and by a group of Australian and New Zealand societies recommend the 24-hour clear fluid approach more broadly than the North American risk-stratified model does.

What The Sleeve Clinic asks

Surgery at The Sleeve Clinic runs to a more conservative instruction than the multisociety guidance permits. Patients stop the GLP-1 at least two weeks before the operation. The 2024 guidance sets out what is defensible across elective surgery generally, including continuing the medication in people without elevated risk of delayed gastric emptying; the clinic's own protocol is stricter than that, and it is the instruction that applies to surgery here.

Two things follow. Reasonable clinicians and institutions land in different places on this, so if your operation is somewhere other than The Sleeve Clinic, the timing that governs it comes from that surgical and anaesthesia team — not from a protocol you read about elsewhere. And the multisociety guidance is explicit that these decisions are shared between the patient and the procedural, anaesthesia and prescribing teams. The two-week stop is arranged with the surgical team and the clinician who prescribes the medication; adjusting or stopping a GLP-1 on your own initiative is not part of that pathway.

Do you have to come off the medication before you can be considered?

No. Assessment and surgery sit at different points on the timeline, and only the second one carries a stopping rule. Nothing has to stop for you to be assessed, and there is a practical argument against treating assessment and medication as sequential: coming off a working treatment while waiting for an appointment can mean regaining weight during exactly the window in which decisions are being made. The stop belongs later in the sequence — at The Sleeve Clinic, at least two weeks before the operation date, planned with the team once a date exists.

Research on people who stayed on GLP-1 therapy in the lead-up to bariatric surgery reports meaningful preoperative weight loss without a clear signal of increased perioperative risk, but the certainty of that evidence is low — the studies are mostly observational, and randomised trials have not yet been done. That is a reason to plan carefully, not a reason to promise anything, and it does not change the two-week stop before surgery here.

If you are still deciding between medication and surgery

Plenty of people who ask this question will stay on a GLP-1, or restart one, and do well. That is a legitimate outcome and a good one, and it is one The Sleeve Clinic can support directly — the clinic prescribes and co-manages weight-loss medication as well as performing surgery, so a consultation here does not have to end in an operation to be worth having. Medication and surgery are not a contest with a winner, and the honest framing is trade-offs: how each option is administered, what it costs and for how long, what it asks of you, its side-effect profile, how reversible each is, and what happens if circumstances change.

Real-world data explain why the question surfaces so often. A US claims cohort found 50.3% of people prescribed a GLP-1 for obesity alone had stopped within 12 months, while an electronic-health-record cohort of 125,474 adults put one-year discontinuation at 64.8% among people without type 2 diabetes and 46.5% among those with it. The spread reflects different populations and different definitions of discontinuation rather than disagreement about the pattern. Cost, access, tolerability and plateaus all appear as reasons. Some people restart, some switch, some hold their weight another way.

One Ontario-specific point belongs here. Bariatric surgery at The Sleeve Clinic is private-pay and is not funded by OHIP — a practical variable in the decision rather than a clinical one, set out on the pricing and financing page.

Medication after surgery is not a contradiction

The 2022 ASMBS and IFSO document states plainly that severe obesity is a chronic disease requiring long-term management after surgery, which may include additional therapy to reach the intended effect. Published series describe GLP-1 therapy being used after bariatric surgery where weight loss has been insufficient or weight has been regained, with reported tolerability broadly consistent with its use outside surgery.

Whether that applies to any individual is a clinical judgement made with the team following them, not a default. It does mean that starting a GLP-1, having surgery, and using medication again later are not mutually exclusive. For people who have their surgery at The Sleeve Clinic, that judgement and any prescription that follows are handled here, since the clinic prescribes and co-manages weight-loss medication as well as operating. If your sleeve was performed at another centre, post-operative care and any medication decision belong with the surgical team who did it. Long-term aftercare and follow-up describes what ongoing monitoring involves.

What to bring to a consultation

Coming prepared shortens the process considerably. Worth writing down:

The medication name, current dose, start date, and when the dose last increased
Any gastrointestinal symptoms, and how often they occur
Who prescribes it, and whether they know you are exploring surgery
Your weight history, including your highest recorded weight and your weight before starting the medication
Other medications and supplements, particularly for diabetes or blood pressure
Previous weight management approaches, medical or otherwise

Common questions

Will I be told to stop my GLP-1 before surgery?

If your surgery is at The Sleeve Clinic, yes — the clinic asks patients to stop at least two weeks beforehand. That is deliberately more conservative than the 2024 multisociety guidance, which supports continuing in most patients without elevated risk of delayed gastric emptying and reserves a preoperative liquid diet or a modified anaesthetic approach for those at higher risk. Protocols differ between centres, so if you are having surgery elsewhere, the instruction that applies to you comes from that surgical and anaesthesia team.

Does losing weight on a GLP-1 mean I no longer qualify?

No single published rule covers this, and programs differ. The Sleeve Clinic assesses current BMI, highest documented BMI and the trajectory across both, so weight lost on medication is read against where you started rather than taken as the whole picture.

Is it dangerous to have surgery while taking a GLP-1?

The specific concern is delayed gastric emptying and aspiration risk under anaesthesia, which is why preoperative assessment asks about dose, formulation, titration phase and gastrointestinal symptoms. The 2024 multisociety guidance concluded most patients can continue, with mitigation for those at higher risk. The Sleeve Clinic takes the more conservative route and asks patients to stop at least two weeks before the operation. All surgery carries risk, assessed individually.

Can I stay on medication after a sleeve?

Some people do. Published series describe GLP-1 use after bariatric surgery for insufficient weight loss or regain, and the surgical societies describe obesity as a chronic condition needing long-term management. Whether it suits a given person is decided with their own team. For patients operated on at The Sleeve Clinic, that conversation happens here; if your sleeve was done at another centre, it belongs with the team who performed it.

Does The Sleeve Clinic only do surgery?

No. The clinic prescribes and co-manages weight-loss medication alongside its surgical practice, so a consultation can lead to medical management rather than an operation. Which route fits is worked out in the consultation rather than settled in advance.

Is any of this covered by OHIP?

Surgery at The Sleeve Clinic is private-pay and not OHIP-funded. Coverage for GLP-1 medications is a separate question that depends on your drug plan and indication.

Before you go further

This article is general education about how GLP-1 treatment and bariatric assessment intersect. It is not medical advice, it cannot tell you whether surgery is appropriate for you, and reading it does not create a patient relationship. Decisions to start, continue, adjust or stop any medication belong to you and the clinician who prescribes it. Approved uses and product information for these medications are published in the Health Canada Drug Product Database. If you develop severe abdominal pain, persistent vomiting or signs of dehydration, contact your physician or attend an emergency department rather than looking for an answer online.

If you want to understand where you actually stand — currently on a GLP-1, tapering off one, or weighing the options against each other — that is what a consultation is for. Bariatric surgery is one option among several, and it is not the right one for everyone. Medication is the other half of what The Sleeve Clinic does in Toronto — weight-loss prescriptions are written and co-managed here — so a consultation can end in medical management, in surgery, or in neither. When you are ready, book a consultation to talk it through, or read more about Dr. Scott Gmora, MD FRCSC FACS and how sleeve gastrectomy works first.

Individual results vary. Consult with Dr. Gmora for a personalized assessment.